Payment overview · 2025
General Payments
$2,158.61
108 reported records · 26 companies
Healthcare provider profile · identity verified
Kenneth J Wolok, DO
Allopathic & Osteopathic Physicians|Family Medicine · STERLING HEIGHTS, MI · NPI 1194715557
Verified facts
What the public records show
CMS Open Payments records show Kenneth J Wolok, DO received $2,158.61 in general payments during 2025 across 108 reported records.
Novo Nordisk Inc accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $467.22 | 21.6% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $295.94 | 13.7% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $274.60 | 12.7% | 15 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $159.88 | 7.4% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $140.39 | 6.5% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $89.77 | 4.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $88.42 | 4.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.26 | 3.4% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $68.19 | 3.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.52 | 2.7% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $48.33 | 2.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $43.45 | 2.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$36.84 | 1.7% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $34.80 | 1.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $31.43 | 1.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.91 | 1.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.17 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.59 | 1.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.66 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.82 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.88 | 0.9% | 1 | 2025 |
| Solta Medical, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.52 | 0.9% | 1 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $18.61 | 0.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.21 | 0.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.37 | 0.8% | 1 | 2025 |
| Validus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.83 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,158.61 | 108 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $442.43 | 21 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $224.85 | 12 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $224.85 | 12 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $224.85 | 12 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $216.33 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $183.84 | 12 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $159.88 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $139.41 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $89.77 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $88.42 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $79.61 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $79.61 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $74.26 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $68.19 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.52 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.75 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.75 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $48.33 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.95 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $36.84 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $31.43 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| CLEAR+BRILLIANT Normalized: clear brilliant |
Not specified | Solta Medical, a division of Bausch Health US, LLC | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| EQUETRO Normalized: equetro |
Drug | Validus Pharmaceuticals LLC | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| RALDESY Normalized: raldesy |
Drug | Validus Pharmaceuticals LLC | $14.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 276 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 177 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
276 | 62 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 918 | 295 |
| Losartan Potassium | Losartan Potassium | 475 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 463 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 107 |
| Metformin Hcl | Metformin Hcl | 327 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 325 | 107 |
| Lisinopril | Lisinopril | 290 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 287 | 53 |
| Eliquis | Apixaban | 276 | 62 |
| Alprazolam | Alprazolam | 264 | 64 |
| Omeprazole | Omeprazole | 246 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 80 |
| Ezetimibe | Ezetimibe | 215 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 61 |
| Simvastatin | Simvastatin | 184 | 50 |
| Donepezil Hcl | Donepezil Hcl | 177 | 35 |
| Jardiance | Empagliflozin | 177 | 47 |
| Sertraline Hcl | Sertraline Hcl | 173 | 45 |
| Furosemide | Furosemide | 172 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 54 |
| Famotidine | Famotidine | 160 | 49 |
| Montelukast Sodium | Montelukast Sodium | 127 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 32 |
| Carvedilol | Carvedilol | 119 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 34 |
| Finasteride | Finasteride | 110 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 32 |
| Potassium Chloride | Potassium Chloride | 107 | 34 |
| Allopurinol | Allopurinol | 94 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 29 |
| Glimepiride | Glimepiride | 85 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 18 |
| Januvia | Sitagliptin Phosphate | 75 | 16 |
| Mounjaro | Tirzepatide | 75 | 17 |
| Tramadol Hcl | Tramadol Hcl | 75 | 29 |
| Meloxicam | Meloxicam | 70 | 30 |
| Bupropion Xl | Bupropion Hcl | 69 | 23 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 68 | 45 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 14 |
| Myrbetriq | Mirabegron | 58 | 11 |
| Ozempic | Semaglutide | 58 | 22 |
| Trazodone Hcl | Trazodone Hcl | 58 | 18 |
| Gabapentin | Gabapentin | 56 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 16 |
| Tradjenta | Linagliptin | 54 | suppressed |
| Azithromycin | Azithromycin | 53 | 46 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Lorazepam | Lorazepam | 52 | 13 |
| Trulicity | Dulaglutide | 50 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 13 |
| Aripiprazole | Aripiprazole | 48 | 11 |
| Diazepam | Diazepam | 48 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 11 |
| Latanoprost | Latanoprost | 47 | suppressed |
| Xarelto | Rivaroxaban | 47 | 11 |
| Bumetanide | Bumetanide | 45 | 13 |
| Ibuprofen | Ibuprofen | 45 | 20 |
| Labetalol Hcl | Labetalol Hcl | 45 | 11 |
| Farxiga | Dapagliflozin Propanediol | 44 | 17 |
| Methylprednisolone | Methylprednisolone | 44 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 16 |
| Metformin Hcl Er | Metformin Hcl | 42 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | 15 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 15 |
| Nystop | Nystatin | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 31 |
| Valacyclovir | Valacyclovir Hcl | 34 | 18 |
| Atenolol | Atenolol | 33 | 11 |
| Fenofibrate | Fenofibrate | 33 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 12 |
| Valsartan | Valsartan | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 15 |
| Dutasteride | Dutasteride | 30 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 29 | 11 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 20 |
| Santyl | Collagenase Clostridium Hist. | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Enulose | Lactulose | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Cilostazol | Cilostazol | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | 13 |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 13 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,158.61 · 108 records | Novo Nordisk Inc | ABRYSVO, AREXVY, CAPLYTA, CAPVAXIVE, CLEAR+BRILLIANT, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EDARBI, ELIQUIS, EQUETRO, EVENITY, GARDASIL 9, GEMTESA, GLYCATE, Grastek, IBSRELA, INCEPTIV, JARDIANCE, KISUNLA, Kerendia, Korlym, NEXLETOL, NURTEC ODT, OTEZLA, Odactra, Ozempic, PREVNAR 20, QULIPTA, RALDESY, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Ragwitek, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, Veozah, Wegovy, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error